Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17940204rdf:typepubmed:Citationlld:pubmed
pubmed-article:17940204lifeskim:mentionsumls-concept:C0023449lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C0040715lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C1522702lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C0017351lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C1415857lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C1538631lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C1825005lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C0599718lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C0599813lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C0599893lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:17940204lifeskim:mentionsumls-concept:C1709634lld:lifeskim
pubmed-article:17940204pubmed:issue1lld:pubmed
pubmed-article:17940204pubmed:dateCreated2007-12-24lld:pubmed
pubmed-article:17940204pubmed:abstractTextTranslocations involving the immunoglobulin heavy chain locus (IGH@) at chromosome band 14q32 are common in mature B-cell neoplasms, but are rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Here, we report the translocation, t(6;14)(p22;q32), involving IGH@ as a novel recurrent translocation in 13 BCP-ALL patients. Fluorescence in situ hybridization and long-distance inverse polymerase chain reaction (PCR) identified ID4 as the partner gene. Breakpoints were scattered over a 19kb region centromeric of ID4. Quantitative real-time PCR showed up-regulation of ID4 mRNA. All patients had deletions of CDKN2A and PAX5 located on the short arm of chromosome 9, frequently as a result of an isochromosome, i(9)(q10) (9/13, 69%). This study defines a new subgroup of BCP-ALL characterized by ID4 over-expression and CDKN2A and PAX5 deletions. Preliminary survival data suggest that this subgroup may be associated with a good response to therapy.lld:pubmed
pubmed-article:17940204pubmed:languageenglld:pubmed
pubmed-article:17940204pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17940204pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17940204pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17940204pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17940204pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17940204pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17940204pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17940204pubmed:statusMEDLINElld:pubmed
pubmed-article:17940204pubmed:monthJanlld:pubmed
pubmed-article:17940204pubmed:issn0006-4971lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:AkasakaTakash...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:ClaviezAlexan...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:SiebertReiner...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:GeskStefanSlld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:HarderLanaLlld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:DyerMartin...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:MoormanAnthon...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:HarrisonChris...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:MazzulloHelen...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:SugimotoKei-J...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:RossFionaFlld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:StreffordJona...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:NagelIngaIlld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:RussellLisa...lld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:MajidAneelaAlld:pubmed
pubmed-article:17940204pubmed:authorpubmed-author:Loraine...lld:pubmed
pubmed-article:17940204pubmed:issnTypePrintlld:pubmed
pubmed-article:17940204pubmed:day1lld:pubmed
pubmed-article:17940204pubmed:volume111lld:pubmed
pubmed-article:17940204pubmed:ownerNLMlld:pubmed
pubmed-article:17940204pubmed:authorsCompleteYlld:pubmed
pubmed-article:17940204pubmed:pagination387-91lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:meshHeadingpubmed-meshheading:17940204...lld:pubmed
pubmed-article:17940204pubmed:year2008lld:pubmed
pubmed-article:17940204pubmed:articleTitlet(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).lld:pubmed
pubmed-article:17940204pubmed:affiliationLeukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.lld:pubmed
pubmed-article:17940204pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17940204pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3400entrezgene:pubmedpubmed-article:17940204lld:entrezgene
entrez-gene:3492entrezgene:pubmedpubmed-article:17940204lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17940204lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17940204lld:entrezgene
lhgdn:association:12958lhgdn:found_inpubmed-article:17940204lld:lhgdn
lhgdn:association:16975lhgdn:found_inpubmed-article:17940204lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17940204lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17940204lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17940204lld:pubmed